See the published version of this preprint at Journal of Nanobiotechnology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
RONG GUI
Central South University Third Xiangya Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7790-0291
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Non-Hodgkin's lymphoma (NHL) possesses great heterogeneity in cytogenetics, immunophenotype and clinical features, and chemotherapy currently serves as the main treatment modality. Although employing monoclonal antibod y targeted drugs has significantly improved its overall efficacy, various patients continue to suffer from drug resistance or recurrence. Chinese medicine has long been used in the treatment of malignant tumors. Therefore, we constructed a low pH value sensitivity drug delivery system based on the cancer cell membrane modified mesoporous silica nanoparticles loaded with traditional Chinese medicine, which can reduce systemic toxicity and improve the therapeutic effect for the targeted drug delivery of tumor cells.
Results: Accordingly, this study put forward the construction of a nano-platform based on mesoporous silica nanoparticles (MSNs) loaded with the traditional Chinese medicine isoimperatorin (ISOIM), which was camouflaged by the cancer cell membrane (CCM) called [email protected] The proposed nano-platform has characteristics of immune escape, anti-phagocytosis, high drug loading rate, low pH value sensitivity, good biocompatibility and active targeting of the tumor site, blocking the lymphoma cell cycle and promoting mitochondrial-mediated apoptosis.
Conclusions: Furthermore, this study provides a theoretical basis in finding novel clinical treatments for lymphoma.
Keywords
Cancer cell membrane, Mesoporous silica nanoparticles, Isoimperatorin, apoptosis, lymphoma
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Journal of Nanobiotechnology.
No community comments so far
Editorial decision: Accept
On 24 Nov, 2020
Editor assigned
On 20 Nov, 2020
Submission checks complete
On 20 Nov, 2020
Editor invited
On 20 Nov, 2020
Version 2
Posted 15 Oct, 2020
No comments provided
Editorial decision: Minor revision
On 24 Oct, 2020
Review #1 received
Received 17 Oct, 2020
Reviewer #1 agreed
On 14 Oct, 2020
Reviewers invited
Invitations sent on 11 Oct, 2020
Editor assigned
On 06 Oct, 2020
Submission checks complete
On 05 Oct, 2020
Editor invited
On 05 Oct, 2020
No comments provided
Editorial decision: Major revision
On 23 May, 2020
Review #1 received
Received 17 May, 2020
Review #2 received
Received 16 May, 2020
Reviewer #2 agreed
On 14 May, 2020
Reviewer #1 agreed
On 06 May, 2020
Reviewers invited
Invitations sent on 05 May, 2020
Editor assigned
On 05 May, 2020
First submitted
On 04 May, 2020
Submission checks complete
On 04 May, 2020
Editor invited
On 04 May, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Nanoscience
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Journal of Nanobiotechnology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
RONG GUI
Central South University Third Xiangya Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0001-7790-0291
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Journal of Nanobiotechnology.
No community comments so far
Editorial decision: Accept
On 24 Nov, 2020
Editor assigned
On 20 Nov, 2020
Submission checks complete
On 20 Nov, 2020
Editor invited
On 20 Nov, 2020
Version 2
Posted 15 Oct, 2020
No comments provided
Editorial decision: Minor revision
On 24 Oct, 2020
Review #1 received
Received 17 Oct, 2020
Reviewer #1 agreed
On 14 Oct, 2020
Reviewers invited
Invitations sent on 11 Oct, 2020
Editor assigned
On 06 Oct, 2020
Submission checks complete
On 05 Oct, 2020
Editor invited
On 05 Oct, 2020
No comments provided
Editorial decision: Major revision
On 23 May, 2020
Review #1 received
Received 17 May, 2020
Review #2 received
Received 16 May, 2020
Reviewer #2 agreed
On 14 May, 2020
Reviewer #1 agreed
On 06 May, 2020
Reviewers invited
Invitations sent on 05 May, 2020
Editor assigned
On 05 May, 2020
First submitted
On 04 May, 2020
Submission checks complete
On 04 May, 2020
Editor invited
On 04 May, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Nanoscience
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Journal of Nanobiotechnology.
Background: Non-Hodgkin's lymphoma (NHL) possesses great heterogeneity in cytogenetics, immunophenotype and clinical features, and chemotherapy currently serves as the main treatment modality. Although employing monoclonal antibod y targeted drugs has significantly improved its overall efficacy, various patients continue to suffer from drug resistance or recurrence. Chinese medicine has long been used in the treatment of malignant tumors. Therefore, we constructed a low pH value sensitivity drug delivery system based on the cancer cell membrane modified mesoporous silica nanoparticles loaded with traditional Chinese medicine, which can reduce systemic toxicity and improve the therapeutic effect for the targeted drug delivery of tumor cells.
Results: Accordingly, this study put forward the construction of a nano-platform based on mesoporous silica nanoparticles (MSNs) loaded with the traditional Chinese medicine isoimperatorin (ISOIM), which was camouflaged by the cancer cell membrane (CCM) called [email protected] The proposed nano-platform has characteristics of immune escape, anti-phagocytosis, high drug loading rate, low pH value sensitivity, good biocompatibility and active targeting of the tumor site, blocking the lymphoma cell cycle and promoting mitochondrial-mediated apoptosis.
Conclusions: Furthermore, this study provides a theoretical basis in finding novel clinical treatments for lymphoma.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Loading...